A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Once-A-Day Tadalafil in Men with Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors

Journal of Sexual Medicine

Volumn 8, Issue 9, 2011, Pages 2617-2624

  Montorsi, Francesco ^a   Aversa, Antonio ^b   Moncada, Ignacio ^c   Perimenis, Petros ^d   Porst, Hartmut ^e   Barker, Clare ^f   Shane, Michael A ^f   Sorsaburu, Sebastian ^f  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c HOSPITAL LA ZARZUELA   (Spain)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^e Private Practice of Urology and Andrology   (Germany)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Erectile Dysfunction; Phosphodiesterase Type 5 Inhibitors; Tadalafil

Indexed keywords

PLACEBO; TADALAFIL;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; HEMATOTHORAX; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERVERTEBRAL DISK HERNIA; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; SEXUAL SATISFACTION; THORAX PAIN; TREATMENT RESPONSE;

EID: 80052503312     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02353.x     Document Type: Article

References (18)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
2. Dorsey P, Keel C, Klavens M, Hellstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother 2010;11:1109-22.
3. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, Munarriz R, Lee SW. Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7:524-40.
4. Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag 2008;4:1315-30.
5. Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep 2003;4:457-65.
6. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004;1:292-300.
7. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2:415-25.
8. Porst H, Giuliano F, Glina S, Ralph D, Casabe AR, Elion-Mboussa A, Shen W, Whitaker JS. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50:351-9.
9. Rajfer J, Aliotta PJ, Steidle CP, Fitch WP, III, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: A randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007;19:95-103.
10. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, Rose L, Lording D, Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008;25:138-46.
11. Porst H, Rajfer J, Casabe A, Feldman R, Ralph D, Vieiralves LF, Esler A, Wolka AM, Klise SR. Long-term safety and efficacy of tadalafil 5mg dosed once daily in men with erectile dysfunction. J Sex Med 2008;5:2160-9.
12. Broderick GA, Donatucci CF, Hatzichristou D, Torres LO, Valiquette L, Zhao Y, Loughney K, Sides GD, Ahuja S. Efficacy of tadalafil in men with erectile dysfunction naive to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. J Sex Med 2006;3:668-75.
13. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009;56:727-35.
14. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, Shen W, Cordell WH. The efficacy and safety of tadalafil: An update. BJU Int 2004;93:1276-81.
15. Mirone V, Costa P, Damber JE, Holmes S, Moncada I, Van AH, Wespes E, Cordell WH, Chan M, Lembo D, Varanese L. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 2005;47:846-54.
16. Aversa A, Bruzziches R, Pili M, Spera G. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 2006;12:3467-84.
17. Frajese GV, Pozzi F, Frajese G. Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. Clin Interv Aging 2006;1:439-49.
18. Eardley I, Gentile V, Austoni E, Hackett G, Lembo D, Wang C, Beardsworth A. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int 2004;94:871-7.